Loading quotes...

Forecast

The analysts' average price target is €107.71 (+38.53%). The median is €110.10 (+41.61%).

Buy	20
Hold	4
Sell	0

News Go to news feed

Biontech records share plunge and closes sites after founders' exit

Biontech has lost massive market value since the COVID peak and is currently trading at around €80, about a quarter of its record high. Founders Uğur Şahin and Özlem Türeci are leaving the company to pursue new research projects, which further weighed on the share price. Biontech is now focusing on research into cancer vaccines and immunotherapies, but at the same time is shutting sites in Germany, risking loss of know‑how and staff despite large cash reserves. » More on t-online.de
BioNTech meets minimum acceptance condition of exchange offer for CureVac

BioNTech announced that by the expiration of the original deadline 184,071,410 CureVac shares (about 81.74% of the issued and outstanding shares) were validly tendered, thereby satisfying the minimum acceptance condition. All tendered shares were accepted; the post-offer period runs until Thursday, 18 December 2025, 6:01 a.m. CET, during which additional shareholders may tender. BioNTech will issue BioNTech ADSs or cash compensation payments for fractions to the tendering CureVac shareholders; non-tendering shareholders will also receive ADSs/cash compensation as part of the post-offer reorganization and their shares will subsequently no longer be tradable on a national exchange. Dutch withholding tax of 15% may generally apply to the BioNTech ADSs issued to non-tendering holders. » More on finanzen.net
Biontech starts public exchange offer for Curevac shares

After approval by the Federal Cartel Office, Biontech is launching a public exchange offer for all outstanding Curevac shares. Curevac shareholders can swap their securities for Biontech ADS, provisionally valued at about $5.46 per Curevac share; the final exchange value will be set five days before the offer ends on 3 December. The management board and supervisory board of Curevac recommend the swap, and major shareholders holding more than 57 percent have already agreed; a minimum acceptance threshold of 80 percent is required. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, BioNTech (ADR) has already paid €2.01 in dividends. The last payout was in June 2022.

Financials

In the last quarter, BioNTech (ADR) had revenue of €105.6M and net profit of -€820.8M

(EUR)	June 2026	YoY
Revenue	105.6M	59.51%
Gross profit	8.6M	95.34%
Net profit	-820.8M	112.31%
EBITDA	-584.7M	67.87%

Fundamentals

Metric	Value
Market capitalization	€19.81B
Number of shares	251.2M
52-week high/low	€111.00 - €71.18
Dividends	No
Beta	1.25
P/E ratio	-11.56
PEG ratio	0.12
P/B ratio	1.11
P/S ratio	7.42

Company profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.